Grover’s disease is an acquired dermatosis of unknown cause histopathologically characterized by the presence of acantholysis. We report an 83-year-old Japanese man who showed multiple pruritic papular lesions distributed bilaterally along Blaschko lines, necessitating the exclusion of segmental Darier’s disease. No mutations in ATP2A2, ATP2C1 or keratin 5 genes were found both in the lesional skin and in peripheral leukocytes, suggesting that putative pathogenesis of Grover’s disease is distinct from those of other acantholytic dermatoses. Electron microscopy revealed poorly developed tonofibrils in the basal cells, and the structure of desmosomes appeared normal, with an increase in the number of desmosomes in the spinous layer, indicating compensation of defective desmosomal function. Impairment of desmosomal plaque proteins linking tonofilaments to desmosomal cadherins may thus account for acantholysis. The unusual bilateral mosaic arrangement in our patient may offer valuable clues to the genetic basis of Grover’s disease.

1.
Parsons JM: Transient acantholytic dermatosis (Grover’s disease): a global perspective. J Am Acad Dermatol 1996;35:653–666.
2.
Fernández-Figueras MT, Puig L, Cannata P, Cuatrecases M, Quer A, Ferrándiz C, Ariza A: Grover disease: a reappraisal of histopathological diagnostic criteria in 120 cases. Am J Dermatopathol 2010;32:541–549.
3.
Weaver J, Bergfeld WF: Grover disease (transient acantholytic dermatosis). Arch Pathol Lab Med 2009;133:1490–1494.
4.
Ringpfeil F, Raus A, DiGiovanna JJ, Korge B, Harth W, Mazzanti C, Uitto J, Bale SJ, Richard G: Darier disease – novel mutations in ATP2A2 and genotype-phenotype correlation. Exp Dermatol 2001;10:19–27.
5.
Li H, Sun XK, Zhu XJ: Four novel mutations in ATP2C1 found in Chinese patients with Hailey-Hailey disease. Br J Dermatol 2003;149:471–474.
6.
Liao H, Zhao Y, Baty DU, McGrath JA, Mellerio JE, McLean WH: A heterozygous frameshift mutation in the V1 domain of keratin 5 in a family with Dowling-Degos disease. J Invest Dermatol 2007;127:298–300.
7.
Sakuntabhai A, Dhitavat J, Burge S, Hovnanian A: Mosaicism for ATP2A2 mutations causes segmental Darier’s disease. J Invest Dermatol 2000;115:1144–1147.
8.
Bolognia JL, Orlow SJ, Glick SA: Lines of Blaschko. J Am Acad Dermatol 1994;31:157–190.
9.
Happle R, Itin PH, Brun AM: Type 2 segmental Darier disease. Eur J Dermatol 1999;9:449–451.
10.
Harboe TL, Willems P, Jespersgaard C, Mølgaard Poulsen ML, Sørensen FB, Bisgaard ML: Mosaicism in segmental Darier disease: an in-depth molecular analysis quantifying proportions of mutated alleles in various tissues. Dermatology 2011;222:292–296.
11.
Powell J, Sakuntabhai A, James M, Burge S, Hovnanian A: Grover’s disease, despite histological similarity to Darier’s disease, does not share an abnormality in the ATP2A2 gene. Br J Dermatol 2000;143:658.
12.
Grosshans EM: Acquired blaschkolinear dermatoses. Am J Med Genet 1999;85:334–337.
13.
Garçon N, Karam A, Lemasson G, Metges JP, Misery L: Paraneoplastic transient acantholytic dermatosis (Grover’s disease) along Blaschko lines. Eur J Dermatol 2009;19:405–406.
14.
Fantini F, Kovacs E, Scarabello A: Unilateral transient acantholytic dermatosis (Grover’s disease) along Blaschko lines. J Am Acad Dermatol 2002;47:319–320.
15.
Liss WA, Norins AL: Zosteriform transient acantholytic dermatosis. J Am Acad Dermatol 1993;29:797–798.
16.
Happle R: Linear Darier’s or Grover’s disease? J Am Acad Dermatol 2003;49:1200–1201.
17.
Hashimoto K, Fujiwara K, Tada J, Harada M, Setoyama M, Eto H: Desmosomal dissolution in Grover’s disease, Hailey-Hailey’s disease and Darier’s disease. J Cutan Pathol 1995;22:488–501.
18.
Grover RW: Transient acantholytic dermatosis. Electron microscope study. Arch Dermatol 1971;104:26–37.
19.
Grover RW, Duffy JL: Transient acantholytic dermatosis. Electron microscopic study of the Darier type. J Cutan Pathol 1975;2:111–127.
20.
Mota AV, Correia TM, Lopes JM, Guimarães JM: Successful treatment of Grover’s disease with calcipotriol. Eur J Dermatol 1998;8:33–35.
21.
Suzuki K, Ochiai T: Darier’s disease; in Hirone T, Suzuki H (eds): Electron Microscopy in Clinical Dermatology, vol 2 (in Japanese). Tokyo, Kodansha, 1989, pp 16–19.
22.
Wang W, Amagai M, Ishiko A: Desmosome splitting is a primary ultrastructural change in the acantholysis of pemphigus. J Dermatol Sci 2009;54:59–61.
23.
Schmieder A, Pasternack SM, Krahl D, Betz RC, Leverkus M: Galli-Galli disease is an acantholytic variant of Dowling-Degos disease: additional genetic evidence in a German family. J Am Acad Dermatol 2012;66:e250–e251.
24.
El Shabrawi-Caelen L, Rütten A, Kerl H: The expanding spectrum of Galli-Galli disease. J Am Acad Dermatol 2007;56:S86–S91.
25.
South AP: Plakophilin 1: an important stabilizer of desmosomes. Clin Exp Dermatol 2004;29:161–167.
26.
Jonkman MF, Pasmooij AM, Pasmans SG, van den Berg MP, Ter Horst HJ, Timmer A, Pas HH: Loss of desmoplakin tail causes lethal acantholytic epidermolysis bullosa. Am J Hum Genet 2005;77:653–660.
27.
Hobbs RP, Amargo EV, Somasundaram A, Simpson CL, Prakriya M, Denning MF, Green KJ: The calcium ATPase SERCA2 regulates desmoplakin dynamics and intercellular adhesive strength through modulation of PKCα signaling. FASEB J 2011;25:990–1001.
28.
Lipsker D, Stark J, Schneider GA: Blaschko-linear dermatitis in adulthood (Grosshans-Marot disease) with antinuclear antibodies. Hautarzt 2000;51:774–777.
29.
Tsubota A, Akiyama M, Sakai K, Goto M, Nomura Y, Ando S, Abe M, Sawamura D, Shimizu H: Keratin 1 gene mutation detected in epidermal nevus with epidermolytic hyperkeratosis. J Invest Dermatol 2007;127:1371–1374.
30.
Weibel L, Harper JI: Linear morphoea follows Blaschko’s lines. Br J Dermatol 2008;159:175–181.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.